Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide()

We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Baba, Hiroaki, Kanamori, Hajime, Oshima, Kengo, Seike, Issei, Niitsuma-Sugaya, Ikumi, Takei, Kentaro, Sato, Yukio, Tokuda, Koichi, Aoyagi, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328613/
https://www.ncbi.nlm.nih.gov/pubmed/32631736
http://dx.doi.org/10.1016/j.jiac.2020.06.022
Descripción
Sumario:We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

Ejemplares similares